Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

26197 Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil

10.1016/j.jaad.2021.06.375 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB88

Author(s):

Tania F. Cestari ◽

Cacilda daSilva Souza ◽

Luna Azulay-Abulafia ◽

Ricardo Romiti ◽

André V.E. Carvalho ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Ongoing Phase

Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.13746 ◽

2016 ◽

Vol 31 (1) ◽

pp. 89-95 ◽

Cited By ~ 36

Author(s):

L. Cai ◽

J. Gu ◽

J. Zheng ◽

M. Zheng ◽

G. Wang ◽

...

Keyword(s):

Plaque Psoriasis ◽

Blind Study ◽

Chinese Patients ◽

Double Blind Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.2.10 ◽

2019 ◽

Vol 3 (2) ◽

pp. 170 ◽

Cited By ~ 1

Author(s):

Abby Van Voorhees ◽

Linda Stein Gold ◽

Mark Lebwohl ◽

Et Al.

Keyword(s):

Plaque Psoriasis ◽

Blind Study ◽

Double Blind Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Abstract not available. Disclosures: Study sponsored by Celgene.

Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12

10.1016/j.jaad.2015.02.939 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB233 ◽

Cited By ~ 1

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)00125-2 ◽

2021 ◽

Vol 397 (10273) ◽

pp. 487-498 ◽

Cited By ~ 6

Author(s):

Kristian Reich ◽

Kim A Papp ◽

Andrew Blauvelt ◽

Richard G Langley ◽

April Armstrong ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Active Comparator ◽

Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study

10.1016/j.jaad.2015.02.937 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB232 ◽

Cited By ~ 1

Keyword(s):

Plaque Psoriasis ◽

Blind Study ◽

Chinese Patients ◽

Double Blind Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Trial Investigating the Efficacy and Safety of Clobetasol Propionate Cream, 0.025% in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.33 ◽

2021 ◽

Vol 5 (6) ◽

pp. s33

Author(s):

Seemal Desai ◽

Zoe Draelos ◽

Steve Feldman ◽

J. Mark Jackson

Keyword(s):

Plaque Psoriasis ◽

Clobetasol Propionate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Parallel Group ◽

Parallel Group Trial ◽

Group Trial

N/A

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)00126-4 ◽

2021 ◽

Vol 397 (10273) ◽

pp. 475-486 ◽

Cited By ~ 5

Author(s):

Kenneth B Gordon ◽

Peter Foley ◽

James G Krueger ◽

Andreas Pinter ◽

Kristian Reich ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Withdrawal Phase

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

The Journal of Dermatology ◽

10.1111/1346-8138.15789 ◽

2021 ◽

Author(s):

Atsuyuki Igarashi ◽

Hidemi Nakagawa ◽

Akimichi Morita ◽

Yukari Okubo ◽

Shigetoshi Sano ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

15190 Whole blood transcriptomic profiling in a phase 3 study of the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp

10.1016/j.jaad.2020.06.213 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB31

Author(s):

Shaojun Tang ◽

Arnaud Amzallag ◽

Robert Yang ◽

Peter H. Schafer

Keyword(s):

Plaque Psoriasis ◽

Whole Blood ◽

Efficacy And Safety ◽

Phase 3 ◽

Transcriptomic Profiling ◽